The recommended dose for LORVIQUA® is 100mg taken orally, once daily. Treatment with LORVIQUA® should be continued until disease progression or unacceptable toxicity.1
Please note: a reduced dose of LORVIQUA® is recommended in patients with severe renal impairment (absolute eGFR < 30 mL/min), e.g. a once daily starting dose of 75 mg taken orally.1
Tablets should be swallowed whole at approximately the same time every day, with or without food. Patients should take a missed dose as soon as it is remembered unless it is less than four hours before their next dose is due, in which case the missed dose should not be taken. Patients should not take two doses at the same time to make up for missed doses.1
Dosing interruption or dose reduction may be required, based on individual tolerability.1
LORVIQUA® dose reduction levels are1:
- First dose reduction: 75mg taken orally once daily
- Second dose reduction: 50mg taken orally once daily
LORVIQUA® should be permanently discontinued if the patient is unable to tolerate the 50 mg dose taken orally once daily.1
Treatment with LORVIQUA® is recommended as long as the patient is deriving clinical benefit from therapy without unacceptable toxicity.1
For the most up-to-date safety information and full information on dose modifications and the management of treatment related adverse events, please refer to the LORVIQUA® Summary of Product Characteristics.
eGFR: Estimated Glomerular Filtration Rate
Stay up to date with the latest relevant healthcare, medical and promotional information about medicines and vaccines promoted by Pfizer.
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-UNP-GBR-7812. January 2024